OrbiMed Increases Stake to 9.99% via $5M Pre-Funded Warrant Purchase in Recent Offering
STTK has more than doubled off its 52-week low of $0.712.
Summary
Institutional investor OrbiMed Advisors increased its stake in Shattuck Labs to 9.99% by participating in a recent public offering, purchasing approximately $5 million in pre-funded warrants.
Key Events · Ownership and Investor Activity · STTK
-
Increased Beneficial Ownership
OrbiMed Advisors, along with its affiliated funds, now beneficially owns 9,021,127 shares, representing 9.99% of Shattuck Labs' common stock.
-
Participation in Public Offering
OrbiMed purchased 1,250,000 pre-funded warrants for approximately $5 million in the company's public offering that closed on June 11, 2026. This follows the 424B5 and 8-K filings on the same date regarding the offering.
-
Strategic Investment
This investment, made at $3.9999 per warrant compared to the current stock price of $4.72, follows a previous PIPE transaction in August 2025 and indicates continued support from a major institutional investor, especially after a dilutive capital raise.
-
Board Representation
Mona Ashiya, a member of OrbiMed Advisors, serves on Shattuck Labs' Board of Directors, aligning the investor's interests with company governance.
Analysis · STTK · Life Sciences
OrbiMed Advisors, a major institutional investor with a board seat, increased its beneficial ownership in Shattuck Labs to 9.99% by purchasing approximately $5 million worth of pre-funded warrants in the company's recent public offering. This significant investment, representing over 1.4% of the company's market cap, demonstrates continued confidence from a key investor following a dilutive capital raise.
At the time of this filing, STTK was trading at $4.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $355M. The 52-week trading range was $0.71 to $8.33. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.